An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers
Latest Information Update: 02 Apr 2025
At a glance
- Drugs AD 228B (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Sponsors Addpharma
- 02 Apr 2025 New trial record